National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 79299 [2024-22123]
Download as PDF
<![CDATA[
79299
Federal Register / Vol. 89, No. 188 / Friday, September 27, 2024 / Notices
individuals and families who are
receiving services under such programs
or initiatives, the gaps in early
childhood home visitation in the state,
and the extent to which such programs
or initiatives are meeting the needs of
eligible families.
(3) The state’s capacity for providing
substance abuse treatment and
counseling services to individuals and
families in need of such treatment or
services.
The SIR provided guidance to states
in updating their statewide needs
assessments and submitting the required
information to HRSA. States that elected
not to apply or be awarded MIECHV
funds were encouraged to work with
nonprofit organizations that received
awards to provide MIECHV-supported
services within the state and determine
whether they will submit their needs
assessments directly or through the
nonprofit organization awardee. HRSA
and recipients providing MIECHV
services within states used the
information collected through the needs
assessment update to ensure the
continued provision of MIECHV home
visiting services in at-risk communities.
The information is also used to support
program planning, improvement, and
decision-making. States wishing to
amend their needs assessment will be
asked to provide new information and
supporting data. HRSA will provide
specific instructions on timeline and the
amendment process to awardees who
request to amend their needs assessment
update in advance of their fiscal year
2025 funding application. HRSA is not
proposing any changes to the previously
approved Needs Assessment SIR.
Likely Respondents: MIECHV Program
Awardees that are states, jurisdictions,
and where applicable, nonprofit
organizations providing services within
states. Based on preliminary interest
expressed by MIECHV awardees to date,
HRSA anticipates that approximately 35
of the 56 awardees may respond to this
opportunity.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below. Burden
hours reflect that existing needs
assessments will be amended rather
than fully developed.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Maternal, Infant, and Early Childhood Home Visiting Program Statewide Needs Assessment Update—Amended
35
1
35
30
1,050
Total ..............................................................................
35
........................
35
........................
1,050
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2024–22182 Filed 9–26–24; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
lotter on DSK11XQN23PROD with NOTICES1
Number of
responses per
respondent
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
17:09 Sep 26, 2024
Jkt 262001
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI SingleSite and Pilot Clinical Trials Study Section.
Date: October 23–24, 2024.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton 940 Rose Avenue
North Bethesda, MD 20852.
Contact Person: YingYing Li-Smerin, MD,
Ph.D. Scientific Review Officer Office of
Scientific Review/DERA National Heart,
Lung, and Blood Institute, National Institutes
of Health, 6705 Rockledge Drive,Room 207–
P, Bethesda, MD 20892–7924 301–827–7942
email: lismerin@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 13, 2024.
Bruce A. George,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–22123 Filed 9–26–24; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 89, Number 188 (Friday, September 27, 2024)]
[Notices]
[Page 79299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22123]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Heart, Lung, and Blood Initial Review Group;
NHLBI Single-Site and Pilot Clinical Trials Study Section.
Date: October 23-24, 2024.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Canopy by Hilton 940 Rose Avenue North Bethesda, MD
20852.
Contact Person: YingYing Li-Smerin, MD, Ph.D. Scientific Review
Officer Office of Scientific Review/DERA National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive,Room 207-P, Bethesda, MD 20892-7924 301-827-7942 email:
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: September 13, 2024.
Bruce A. George,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-22123 Filed 9-26-24; 8:45 am]
BILLING CODE 4140-01-P
